Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2019-06-04 DOI:10.2217/hep-2019-0001

Jean-Luc Raoul, Jean-Sébastien Frenel, Judith Raimbourg, Marine Gilabert

引用次数: 28

Abstract

Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosine kinase inhibitor available in first line, lenvatinib, three other targeted therapies in second line post-sorafenib (regorafenib, cabozantinib and ramucirumab) and promising data from two immunotherapies (nivolumab and pembrolizumab). Unfortunately, no biomarkers have been identified to help guide our choice. In this short review we summarize the results of these different therapies and propose a therapeutic algorithm based on subgroup analysis. It is most likely that we will not have head-to-head comparisons in second line trials.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝细胞癌系统治疗的当前选择和未来可能性。

大多数肝细胞癌患者在治疗后不能从疾病复发中获益或经历疾病复发。2007年，索拉非尼在晚期肝细胞癌的一线治疗中显示出疗效。经过十年的阴性试验，2019年初，我们在一线有了另一种酪氨酸激酶抑制剂乐伐替尼，在索拉非尼后的二线有了其他三种靶向疗法（瑞戈非尼、卡博扎替尼和拉穆丘单抗），以及两种免疫疗法（尼沃单抗和pembrolizumab）的有希望的数据。不幸的是，目前还没有发现有助于指导我们选择的生物标志物。在这篇简短的综述中，我们总结了这些不同疗法的结果，并提出了一种基于亚组分析的治疗算法。我们很可能不会在二线试验中进行正面比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.